Rhythm Pharmaceuticals, Inc. (RYTM) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boston, MA, United States. The current CEO is David Meeker.
RYTM has IPO date of 2017-10-09, 283 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $5.96B.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of therapeutics for rare genetic diseases of obesity. The company's lead product, IMCIVREE, is a melanocortin-4 receptor agonist approved for treating obesity caused by POMC, PCSK1, and LEPR deficiencies, as well as Bardet-Biedl and Alström syndromes. Rhythm is also advancing setmelanotide through Phase II clinical trials for multiple rare genetic obesity indications, including heterozygous POMC or LEPR deficiency, SH2B1 deficiency, MC4 receptor deficiency, and Smith-Magenis syndrome. Founded in 2008 and formerly known as Rhythm Metabolic, Inc., the company collaborates with leading clinical research organizations to advance its pipeline and address significant unmet medical needs in rare genetic obesity.
